《Hims & hers Health》的股份在Trump的FDA选择中上升了20%, Marty Makary博士, 被视为潜在的监管盟友。 Shares of Hims & Hers Health jump 20% on Trump's FDA pick, Dr. Marty Makary, seen as a potential regulatory ally.

在当选总统唐纳德·特朗普提名马蒂·马卡里博士为FDA负责人后，Hims & Hers Health的股票飙升了20%以上。 Hims & Hers Health shares surged by over 20% after President-elect Donald Trump nominated Dr. Marty Makary as the head of the FDA. Makary是Sesame的远程保健和执行的倡导者,该公司出售复合重量损失药物,有可能对Hims的监管环境带来有利的变化。 Makary, an advocate for telehealth and executive at Sesame, a company that sells compounded weight-loss drugs, could potentially bring favorable changes to the regulatory landscape for Hims & Hers. Hunterbrook Capital最近在该公司的长期地位支持了这种乐观态度,并引述了马卡里领导的潜在好处。 This optimism is supported by Hunterbrook Capital’s recent long position in the company, citing potential benefits from Makary's leadership. 然而,华尔街仍然持谨慎态度,许多分析家保持持有或出售评级。 However, Wall Street remains cautious, with many analysts maintaining hold or sell ratings.